Immune Monitoring Unit

Specific immunotherapy is a promising treatment option for various tumor patients. Immunotherapeutic strategies comprise the vaccination of tumor peptides and immunostimulatory adjuvants, the application of monoclonal and bispecific antibodies as well as the adoptive transfer of non-modified and chimeric antigen receptor- or T cell receptor-engineered T lymphocytes.

The concomitant monitoring of the frequency, phenotype and functional properties of different immune cell populations is of essential importance to understand clinical responses and side effects caused by the treatment. Moreover, immune monitoring enables the identification of novel treatment-related prognostic and predictive biomarkers.

The major task of the immune monitoring unit is the analysis of the phenotype and functional properties of different immune cell populations in the context of clinical trials. Moreover, such studies support the design of improved immunotherapeutic strategies for tumor patients.

Service (selection)

  • Monitoring of different immune cell populations in the patient blood during clinical studies
  • Phenotypic and functional characterization of different immune cell populations in tumor samples and tumor-free tissues
  • Consulting service for the design of immune monitoring for translational research projects and clinical studies

Methods

  • Evaluation of tumor-specific T cells (ELISPOT/FACS)
  • Analysis of cytokine expression profiles of immune cells (FACS/ELISA/Immunofluorescence)
  • Phenotyping of immune cells (FACS/Immunohistochemistry/Immunofluorescence)
  • Analysis of antibodies (Immunohistochemistry/Immunofluorescence)
  • Functional assays for immune cells [FACS/ELISA/Radioactivity assays (Cr51/3H-Thymidine)]
  • FACS-based single cell sorting
  • T cell cloning
  • T cell receptor sequencing
  • Transcriptomics
  • HLA classification
Immune Monitoring

Characterisation of the tumor immune architecture by using the Vectra®3.0 system from PerkinElmer (automated multispectral imaging technology) Copyright: Uniklinik Dresden/Gabriele Bellmann

Head

Prof. Dr. Marc Schmitz
Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden
Tel.: + 49 (0) 351 4586501
E-Mail: marc.schmitz(at)tu-dresden.de

Coordination

Dr. Rebekka Wehner
Institute of Immunology, Medical Faculty Carl Gustav Carus, TU Dresden
Tel.: + 49 (0) 351 45816524
E-Mail: rebekka.wehner(at)tu-dresden.de

Staff

Dr. Antje Tunger
National Centre for Tumor Diseases Dresden
Tel.: + 49 (0) 351 4586528
E-Mail: antje.tunger(at)nct-dresden.de

Cathleen Rüger
National Centre for Tumor Diseases Dresden
Tel.: + 49 (0) 351 45816528
E-Mail: cathleen.rueger(at)nct-dresden.de